about
An Evolutionary Framework to Understand Foraging, Wanting, and Desire: The Neuropsychology of the SEEKING SystemPharmacological treatment for depression during opioid agonist treatment for opioid dependenceKappa-opioid ligands in the study and treatment of mood disordersDetermining effective methadone doses for individual opioid-dependent patientsNeurobiology of opioid dependence in creating addiction vulnerabilitySex Differences in Kappa Opioid Receptor Function and Their Potential Impact on AddictionBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewAssessment and treatment of mood disorders in the context of substance abuseRole of kappa-opioid receptors in stress and anxiety-related behavior.Biomarkers of epileptogenesis: psychiatric comorbidities (?)Affective preclinical modeling of psychiatric disorders: taking imbalanced primal emotional feelings of animals seriously in our search for novel antidepressantsInvited review: the evolution of antidepressant mechanismsSynthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor ModulatorsIn Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data fusion.Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates.Psychotherapeutic benefits of opioid agonist therapy.Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in miceEvaluation of opioid modulation in major depressive disorderAntidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.Major Depressive Disorder and Kappa Opioid Receptor Antagonists.A role for the mu opioid receptor in the antidepressant effects of buprenorphine.Investigational drugs in recent clinical trials for treatment-resistant depression.The multi-site prescription opioid addiction treatment study: 18-month outcomesProof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Affective neuroscience of the emotional BrainMind: evolutionary perspectives and implications for understanding depression.Antidepressant-like effects of buprenorphine in rats are strain dependent.Psychometric Evaluation of the Substance Use Risk Profile Scale (SURPS) in an Inpatient Sample of Substance Users Using Cue-Reactivity MethodologyDepression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuseLong-term retention in Office Based Opioid Treatment with buprenorphine.Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal ModelsPotentiation strategies for treatment-resistant depression.Effects of buprenorphine on responses to social stimuli in healthy adults.Development of κ opioid receptor antagonists.Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain.Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.
P2860
Q22242984-B1B8515C-8E24-455F-AC9C-353ADF2AA379Q24235458-98F3453B-D080-44A4-B04A-BE2FDD257984Q24657982-556BF1B0-3508-42CF-A7D5-1F840C37CBE5Q25255226-94036EDF-AB93-4AD1-BE61-D718C6D67A7AQ26742048-205D01F9-0D4F-4E93-B689-AA15696FD6A6Q26770785-B2F79538-0C4E-4CE5-A5B3-9B7821614DA0Q26782993-5F01658C-6C79-409E-954B-053E00BA90DCQ26798232-E394541F-0F46-4FB4-8A5D-2494182226BAQ26991739-0E7C4491-66F6-49B8-AC9E-0591155B0F69Q27015612-F3C79A2E-5F68-407F-92A4-C2B7B9CDC2AEQ28068011-547623E7-2E65-43D2-A5A2-FFD1EC19D03FQ28241221-D5A0E5B0-19B8-4E4B-814A-521EE5F1A06CQ28275620-47C7A4C9-3102-475A-AEBA-89DD6D822F55Q30833986-B7233A4E-E61A-446C-9200-944B00C2B280Q31147169-4BDE711F-6E73-4BAC-9674-DDAF68B29432Q33981287-93B1DA74-5081-41C0-A459-5388236DA91BQ34014407-283F13FE-A0E9-4125-B7FF-372BB152E8C4Q34147541-A3BC615F-EFC1-4F1E-BCD5-4DB0056767BAQ34409641-D2047638-D907-4A2C-8834-9A997E90976AQ34436340-0F9743F1-8AC7-47C9-8BF0-22D007A3F59CQ34454397-4461AAAD-B113-4E1B-8C79-A6CA9A42671CQ34518271-CBAD4775-224F-4956-9D57-F9508A075788Q34527874-49A8824E-4C63-4C99-AA15-6A8AEA5A44E1Q34544184-A6915B9E-4CEF-482E-ADF7-44095CA87E10Q34549390-DF02E70C-81AB-43C7-AE5A-45D65D9C1318Q34602946-9C5503E3-1226-4419-8312-4285E05EC902Q34766451-8F50F831-A5AD-4247-B0EF-D7C7F4ECE7C6Q34952233-3D8E1C78-C2F1-4B54-B55B-089E6F801E20Q35237295-3DA6CFA6-F14F-4C9A-A18C-B540317846EBQ35243233-46A4466D-959E-4F6A-879E-FAA54C94486FQ35684558-DFCB2362-1579-4B94-A9C2-D969C064D055Q36083505-358B8BD5-8C58-433B-A745-7F330E311C7BQ36263379-70F3BDCC-EED0-4E13-8149-67C93903334FQ36310509-7A7C5463-992F-4369-8649-99003CF3C25AQ36322234-C0964EE4-F62D-4340-B367-DBC7C02F61F1Q36414570-E4B244DD-0284-4FA7-91AA-AB0586F570F9Q36728154-02DF7C03-60F8-4B20-B6EC-272BBFE25C6BQ36800122-5AC894A8-4A60-4BF9-AB4E-778E6EB3C622Q36996884-3DBC163F-ECDB-4830-B32B-6876E0A66DBEQ37311873-E4E6379E-64E9-4B52-BE62-59EF7C8D0F71
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Buprenorphine treatment of refractory depression.
@ast
Buprenorphine treatment of refractory depression.
@en
Buprenorphine treatment of refractory depression.
@nl
type
label
Buprenorphine treatment of refractory depression.
@ast
Buprenorphine treatment of refractory depression.
@en
Buprenorphine treatment of refractory depression.
@nl
prefLabel
Buprenorphine treatment of refractory depression.
@ast
Buprenorphine treatment of refractory depression.
@en
Buprenorphine treatment of refractory depression.
@nl
P2093
P1476
Buprenorphine treatment of refractory depression.
@en
P2093
P356
10.1097/00004714-199502000-00008
P407
P577
1995-02-01T00:00:00Z